Sugi Predict

Sugi Predict / Compounds / SCHEMBL2932631

SCHEMBL2932631

SCHEMBL2932631

CC1C(=O)N(c2ccc(S(=O)(=O)C(F)(F)F)cc2)C(=O)N1Cc1ccncc1N

nearest known ligand 0.66

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 2/20 0.66
▸ SMO Q99835 4/20 0.39
▸ HRH4 Q9H3N8 1/20 0.34
▸ AOC1 P19801 2/20 0.33
▸ AOC3 Q16853 2/20 0.33
▸ CTSS P25774 1/20 0.33
▸ LMNA P02545 2/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ CHRM4 P08173 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ MBOAT4 Q96T53 1/20 0.31
▸ TAS2R8 Q9NYW2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2936676 0.90 IGF1R (0.66) IGF1RSMOHRH4CTSSLMNA
SCHEMBL2936802 0.89 IGF1R (0.67) IGF1RSMOCTSSTAS2R8
SCHEMBL2936799 0.89 IGF1R (0.67) IGF1RSMOCTSSTAS2R8
SCHEMBL2932195 0.89 IGF1R (0.67) IGF1RSMOHRH4CTSSLMNA
SCHEMBL2939398 0.89 IGF1R (0.67) IGF1RSMOHRH4CTSSLMNA
SCHEMBL2936954 0.89 IGF1R (0.67) IGF1RSMOHRH4CTSSLMNA
SCHEMBL2999392 0.89 IGF1R (0.67) IGF1RSMOCTSSTAS2R8
SCHEMBL2942027 0.88 IGF1R (0.66) IGF1RSMOCTSSLMNAMAPK1
SCHEMBL2939259 0.87 IGF1R (0.68) IGF1RSMOCTSSLMNAMAPK1
SCHEMBL3732628 0.87 IGF1R (0.65) IGF1RSMOHRH4CTSSLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 IGF1R 1595/4885SMO 2187/4885HRH4 3794/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA IGF1R 962/4885SMO 2697/4885HRH4 3038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.